RM
Ryan D Maynard
Director

Ryan D Maynard insider trades: Iovance Biotherapeutics (IOVA) stock buys and sales

Director, Iovance Biotherapeutics Last trade Nov 12, 2024 40 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2012
5
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ryan reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 12, 2024IOVA↓ Sell$503K
Feb 8, 2023CARA↓ Sell$3K
May 31, 2022IOVA↑ Buy$51K
Nov 3, 2017RIGL↓ Sell10b5-1$390K
Sep 10, 2012RIGL↓ Sell$545K
Sep 7, 2012RIGL↓ Sell$249K
Aug 7, 2012RIGL↓ Sell$18K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Ryan D Maynard's insider trades

Ryan D Maynard is a director at Iovance Biotherapeutics (IOVA). Since Aug 7, 2012, Ryan has reported 1 open-market purchase worth $51K and 6 sales worth $1.7M on SEC Form 4. There have been no open-market trades in the last 12 months.

1 sale (23% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.

Their filings also include grants and awards (33 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IOVA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.